title: Systemic effects of fluticasone nasal spray: report of 2 cases.
abstract: OBJECTIVE
  To describe two clinical cases of systemic side effects from use of fluticasone nasal spray.
  
  
  METHODS
  A retrospective review of medical records of two patients using this drug was undertaken, and their clinical presentations and laboratory data are summarized.
  
  
  RESULTS
  Despite many clinical reports about the potential side effects from inhaled corticosteroids, no previously published clinical reports or studies have addressed such problems with the use of potent glucocorticoid nasal sprays. Two patients are described in whom different clinical problems developed after overuse of fluticasone nasal spray, a commonly advertised and prescribed drug. One patient was admitted to the hospital with symptoms of adrenal insufficiency. In the other patient, bone mineral density decreased substantially in 1 to 2 years despite preventive estrogen therapy. These patients had suppressed plasma or urinary cortisol, a low plasma adrenocorticotropic hormone (corticotropin) level, or an abnormal response to a cosyntropin stimulation test.
  
  
  CONCLUSIONS
  Patients should be clearly warned that the prescribed dosing for fluticasone nasal spray should be carefully followed because overuse may cause serious side effects.
authors.affiliation: Department of Endocrinology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA.
authors.forename: Angelo A
authors.initials: AA
authors.lastname: Licata
mesh_terms: D000224:Addison Disease / Q000139:chemically induced; D000281:Administration, Intranasal; D000307:Adrenal Gland Diseases / Q000139:chemically induced; D000324:Adrenocorticotropic Hormone / Q000097:blood; D000730:Androstadienes / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D015914:Estrogen Replacement Therapy; D012968:Etidronic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D005260:Female; D000068298:Fluticasone; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000139:chemically induced; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy; D000068296:Risedronic Acid
chemical_list: D000730:Androstadienes; D018926:Anti-Allergic Agents; D000324:Adrenocorticotropic Hormone; D000068298:Fluticasone; D000068296:Risedronic Acid; D012968:Etidronic Acid; D006854:Hydrocortisone